Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intravenous Human Immunoglobulin (Xinjiang Deyuan Bioengineering)
- Development stage
- Unknown
- Lead developer
- Xinjiang Deyuan Bioengineering
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Intravenous Human Immunoglobulin (IVIG) from Xinjiang Deyuan Bioengineering is a plasma-derived biologic product composed of pooled human immunoglobulin G (IgG) antibodies. It is manufactured from the plasma of healthy donors and contains a broad spectrum of antibodies against various pathogens and antigens. The mechanism of action involves the passive transfer of these antibodies to provide immediate immunity through the neutralization of pathogens and toxins, as well as immunomodulation in autoimmune or inflammatory conditions via interaction with Fc receptors and the complement system. It is primarily indicated for the treatment of primary immune thrombocytopenia (ITP), primary immunodeficiency diseases, and other immune-mediated disorders. The product is approved in China and is available in 5% concentrations in various volumes.
- Brand names
- 静注人免疫球蛋白
- Other names
- IVIGIntravenous Human ImmunoglobulinXinjiang Deyuan IVIG
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)C1Q (Complement C1q)
Beyond the preview
Go deeper on Intravenous Human Immunoglobulin (Xinjiang Deyuan Bioengineering).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intravenous Human Immunoglobulin (Xinjiang Deyuan Bioengineering).